Other languages Oncopeptides AB

Equities

ONCO

SE0009414576

Market Closed - Nasdaq Stockholm Other stock markets 11:29:59 2024-04-26 am EDT			5-day change	1st Jan Change
2.955 ^SEK	+2.25%		-26.12%	-61.42%

Apr. 15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI
Apr. 04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	Apr. 15
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	Mar. 13
Oncopeptides AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Oncopeptides AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Ça fait beaucoup de records	Feb. 26
En Direct des Marchés : Saint-Gobain, Sanofi, Stellantis, Casino, Berkshire Hathaway, Alcoa, Tele2...	Feb. 26
EN DIRECTO DESDE LOS MERCADOS: Acciona, ArcelorMittal, Iberdrola, Inditex, Sabadell, IAG, Aena, Vidrala, Prosegur...	Feb. 26
Oncopeptides to Assess US FDA's Withdrawal of Blood Cancer Drug Approval	Feb. 23
Spanish Authority Gives Positive Recommendation for Pricing of Oncopeptides' Blood Cancer Drug	Feb. 23
Oncopeptides Receives Positive Recommendation for Pepaxti by Spanish Pricing Authority	Feb. 23
Oncopeptides Extends Exclusive Rights to Cancer Drug Until 2037	Feb. 15
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines	Dec. 15
Oncopeptides' New CFO Takes Office	Nov. 13
Oncopeptides Selects to Present Additional Data from Ocean Study	Nov. 13
Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Oncopeptides AB Announces the Nomination Committee	23-10-20
Oncopeptides AB Announces Its Decision to Adopt the Application Process to Allow Pertide Access to Patients with Relapsed, Refractory Multiple Myeloma	23-09-28
Oncopeptides Secures EU Committee Backing for Expanded Indication of Multiple Myeloma Therapy; Shares Surge	23-09-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oncopeptides AB

Equities

ONCO

SE0009414576

Other languages

Filters